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CLINICAL INVESTIGATION
Prevention of glomeruloscierosis by early cyclosporine treatment
of experimental lupus nephritis
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Department of Pathology, Universily of Leiden, Leiden, The Netherlands
Prevention of glomeruloscierosis by early cyclosporine treatment of
experimental lupus nephritis. The influence of cyclosporine A (CsA)
treatment on the development of glomerulonephritis and glomeruloscie-
rosis was investigated in chronic graft-versus-host disease (GvHD), a
murine model for lupus nephritis. The renal disease is characterized by the
formation of IgG-containing electron-dense deposits along the glomerular
basement membrane (GBM) and in the mesangium, followed by the onset
of proteinuria which starts, vaiying per individual mouse, about six weeks
after the induction of the disease. Glomerular mRNA levels for matrix
molecules were increased from week 4, preceding mesangial matrix
expansion and GBM thickening which occurred from week 6. These initial
events finally led to development of glomerulosclerosis, and end-stage
renal failure. Groups of mice received three intraperitoneal (i.p.) injec-
tions per week with different doses of CsA, and treatment was started 2,
4, or 6 weeks after induction of the disease. Treatment with 10 or 50 mg
CsA/kg/week did not influence the development of glomerulonephritis or
glomerulosclerosis. Injection of 100 mg CsAJkg/week delayed the onset of
proteinuria only when treatment was started in week 2. In week 6 some
mice had already developed proteinuria whereas others had not. Treat-
ment with 250 mg CsAlkglweek starting in week 6 abrogated glomerulo-
nephritis and glomerulosclerosis only in those animals which were not yet
proteinuric at that time. This, despite comparable increased autoantibody
levels against DNA, GBM, and renal tubular epithelium (RTE) in both
treated and untreated GvHD mice. Further increase in proteinuria and
development of glomerulosclerosis could not be prevented if the mice
already had developed proteinuria when CsA treatment was started. Dot
blot analysis and in situ hybridization showed significantly decreased
mRNA levels for al(I) and al(IV) collagen in kidneys of CsA-treated
mice as compared to those of untreated mice 12 weeks after induction of
the disease, if the highest dose of CsA was administered before the onset
of proteinuria. No effect on these whole-kidney mRNA levels was
observed in mice which had already developed proteinuria before CsA
injections were started. Increased mRNA expression for matrix molecules
in this group and in untreated GvHD mice was observed mainly in the
interstitium. The kidneys of the treated GvHD mice and those of mice
injected with 250mg C5A/kglweek without induction of GvHD showed no
morphological signs of CsA nephrotoxicity. We conclude that treatment
with 250 mg CsA/kg/week prevents the development of glomerulonephri-
tis and glomerulosclerosis in this model of lupus nephritis, if started before
the onset of proteinuria. This might result from a direct effect of CsA on
matrix synthesis, since autoimmunity was not affected as reflected by
unaltered autoantibody levels, which increased to a similar extent in both
treated and untreated animals. Furthermore, our results may indicate the
possible diagnostic and prognostic value of extracellular matrix steady-
state mRNA levels in early stages of renal disease.
Immunologically-mediated kidney diseases often lead to develop-
ment of glomeruloscierosis, an irreversible end-stage renal compli-
cation with a poor prognosis for the patient. It is still unclear how the
development of glomerulosclerosis can be prevented by early
therapeutic intervention. In this manuscript we describe the influ-
ence of treatment with the immunosuppressive agent cyclosporine A
(CsA) on the development of glomerulonephritis and glomeruloscie-
rosis in chronic graft-versus-host disease in mice, a model for lupus
nephritis [1].
Induction of GvHD in (DBA/2 * C57BL1O)F1 hybrid mice by
transfer of anti-allo class II CD4+ donor T cells, results in uncon-
trolled B-cell activation and production of autoantibodies [2—6].
IgG-containing electron-dense deposits are formed subendothelially
and subepithelially along the GBM and in the mesangial matrix,
coinciding with the onset of proteinuria [7]. Six weeks after induction
of chronic GvHD expansion of the mesangial matrix and thickening
of the GBM are observed. In the final stage (week 10 to 12) of (JvHD
glomerulosclerosis develops [7].
The immunosuppressive drug CsA is currently believed to inhibit
primarily the activation of T helper/inducer and B-lymphocytes by
interference with the synthesis and release of interleukins, especially
interleukin-2 (IL-2) [8, 9]. CsA has been shown to prevent and
ameliorate both organ-specific [10, 11] and systemic [12, 131 experi-
mental autoinimunity.
In the present study we investigated the effect of CsA treatment on
the development of proteinuria, autoantibody production, extracel-
lular matrix (ECM) expansion, and development of glomeruloscle-
rosis in the GvHD modeL A pilot study had shown that i.p. injection
of 100 mg CsA/lg/week into mice suffering from GvHD delayed the
development of glomerulonephritis and glomerulosclerosis only
when treatment was started two weeks after the induction of the
disease, but not later. Therefore, in this study we started CsA
administration in week 2 when the effects of different doses of CsA
were compared. It appeared that administration of 250 mg CsAJkg/
week prevented the development of glomerulonephritis and glomer-
ulosclerosis. In an additional experiment we showed that this high
dose of CsA prevented the development of glomerulonephritis and
glomeruloscierosis in chronic GvHD also when treatment was started
later in the disease, but only if there were still no signs of proteinuria,
although a slight increase in ECM mRNA levels was observed.
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Methods
Animals
C57B1110 (H2M) and DBA/2 (H-2") mice were purchased
from Olac 1976 Ltd. (Bicester, Oxfordshire, UK). (C57BLJ1O*DBA/
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2)F1 hybrid mice were bred in our animal facilities. For the present
study we used 105 experimental Fl mice and three age- and
sex-matched control mice.
Experimental design
Chronic GvHD was induced in (C57BL/10*DBA/2)F1 female
hybrid mice aged 8 to 10 weeks (N = 84) by four intravenous
injections with lymphocytes from female DBA/2 donor mice aged
7 to 8 weeks at three to four day intervals. CsA treatment was
performed by giving three intraperitoneal injections per week,
three, one injection on Mondays, one on Wednesdays, and one on
Fridays. CsA (SandimmuneR, Sandoz AG, Basel, Switzerland)
was diluted in 0.5 ml physiologic salt solution per injection.
In the first experiment CsA treatment was started two weeks
after the first injection with lymphocytes. The protocol was as
follows:
Group 1A (N = 14): GvHD
Group 18 (N 14): GvHD, CsA 10 mg/kg body wt/week
Group l (N = 14): GvHD, CsA 50 mg/kg body wt/week
Group 1D (N = 14): GvHD, CsA 100 mg/kg body wt/week
Group 1n (N = 8): GvHD, CsA 250 mg/kg body wt/week
Group 1F (N = 6): CsA 100 mg/kg body wt/week
Group 1G (N = 6): CsA 250 mg/kg body wt/week
For all groups except for Group 1A, CsA treatment was divided
over three injections per week, each injection containing one third
of the total dose indicated.
In the second experiment mice were divided into two groups six
weeks after the induction of GvHD: a group in which individual
mice already showed proteinuria, and a group in which the mice
had not developed proteinuria. From that moment on both groups
were treated with 250 mg CsAJkg/week. An additional group of
mice was treated with 250 mg CsA/kg/week from week 4 on, a
moment at which none of the animals were proteinuric.
Group 2A (N 4): GvHD
Group 28 (N = 4): GvHD, CsA 250 mg/kg/week starting at
week 4
Group 2 (N = 6): GvHD, CsA 250 mg/kg/week starting at
week 6, non proteinuric at week 6
Group 2' (N = 6): GvHD, CsA 250 mg/kg/week starting at
week 6, proteinuric at week 6
Except for group 2A, CsA treatment was divided over three
injections per week, each injection containing one third of the
total dose indicated.
In both experiments the urine albumin content and the serum
autoantibody levels of individual mice were determined one week
before and four weeks after the first injection of parental cells and
then at two-weekly intervals as described below. In experiment
1 groups of three mice each were sacrificed in week 4 and week 6
for direct immunofluorescence studies. The other mice were
sacrificed 12 weeks after induction of the disease. After perfusion
with phosphate-buffered salt solution (PBS), the kidneys were
removed. Part of the tissue was fixed in 4% buffered formalin,
dehydrated, and then embedded in ParaplastR (Amstelstad, Am-
sterdam, The Netherlands) for light microscopy, and for in situ
hybridization studies in experiment 2. The remaining kidney tissue
was frozen in CO2 ice-cooled isopentane and stored at —70°C
until use for immunofluorescence and RNA studies. Kidney
tissues of normal Fl hybrids, used as controls in light microscopy,
dot blot and in situ hybridization studies, were treated in the same
way.
In an additional control experiment a group of untreated mice
(N = 9) was divided six weeks after induction of GvHD into a
subgroup of animals which were already proteinuric (N = 5), and
a subgroup of animals which did not show proteinuria (N = 4).
Twelve weeks after the induction of GvHD both subgroups were
again examined for the albumin content of their urines.
Induction of GvHD
Spleens, lymph nodes (mesenteric, cervical, and inguinal) and
thymi from DBA/2 donors were removed under aseptic condi-
tions. Single cell suspensions were prepared by mincing the tissue
in sterile Hanks' balanced salt solution (HBSS) and gently press-
ing the fragments through a steel sieve (150 m pore size). The
suspensions were then filtered through a nylon sieve (71 tm pore
size), after which the cells were passed through a sterile Pasteur
pipette loosely packed with cotton wool. The suspensions were
washed three times in HBSS and centrifuged for 10 minutes at
250 X g. The pellets were resuspended in HBSS. The total
number of cells and the proportion of vital cells were determined
by Trypan blue exclusion and phase contrast microscopy. The
suspensions were mixed. On days 0, 3, 7, and 10, the Fl recipients
were injected intravenously with 50* 106 viable DBA/2 cells in 0.25
ml HBSS. Each dose was composed of approximately 60% spleen
cells, 30% thymocytes and 10% lymph node cells.
Albuminuria
To determine the albumin levels in the urines, mice were kept
in urine collection cages for 18 hours with free access to water and
food. The albumin levels were assessed by rocket electrophoresis
against rabbit anti-mouse albumin, which had been produced by
immunization of a rabbit with purified mouse serum albumin
(Sigma Chemical Corporation, St. Louis, Missouri, USA). This
mouse albumin was also used as standard [14].
Serum samples
After urine collection, the mice were anesthetized with dieth-
ylether and blood was collected from the orbital plexus. Serum
samples were tested for the presence of autoantibodies by en-
zyme-linked immunosorbent assay (ELISA) performed as men-
tioned earlier [3]. Results from each sample were corrected for
non-specific binding to bovine serum albumin (BSA). For the
ELISA studies, RTE and GBM were prepared from fresh
(C57BL1O X DBAJ2)F1 mouse kidneys, and the purity of these
antigens was verified by absorption studies, gel electrophoresis,
ELISA, and immunoblotting as described [15, 16]. Calf thymus
double-stranded (ds) DNA was purchased from Pharmacia P-L
Biochemicals, Inc. (Milwaukee, Wisconsin, USA). Single-stranded
(ss) DNA was prepared by denaturation of dsDNA at 100°C.
Histological techniques
The kidney tissue was processed for light microscopy and
immunofluorescence studies as described elsewhere [3]. The
sections for light microscopy were stained with periodic acid-
Schiff (PAS), hematoxylin-eosin (HE), and methenamine-silver.
The immunofluorescence slides were scored in a double-blinded
fashion by two observers independently of each other.
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Antibodies
We used rabbit anti-mouse IgG-FITC, rabbit anti-mouse 1gM-
FITC, and goat anti-mouse C3-FITC obtained from Nordic (Tilburg,
The Netherlands). Affinity-purified goat anti-type I collagen anti-
serum was purchased from Sera-lab (Sussex, UK), and rabbit anti-
goat IgG-FITC (Nordic) was used as a second antibody. Monoclonal
antibodies against CD3 were purchased from Pharmingen (San
Diego, California, USA). Antibody specificities were determined
using indirect and direct ELISA, indirect immunofluorescent stain-
ing, indirect immunocytochemistiy, and dot blotting techniques.
Northern and dot blot analyses
Total RNA was purified from whole kidney tissue according to
Chirgwin et a! [17]. Whole kidney tissue was directly homogenized
in lytic solution using an ultra-turrax T25 (Janke & Kunkel,
IKA-labortechnik, Heitersheim, Germany). The RNA was quan-
titated by measuring the absorbance at 260 nm.
Northern and dot blot analysis were performed as described
elsewhere [18]. Aliquots of 20 jig RNA were denatured in a
solution containing 50% deionized formamide, 2.2 M formalde-
hyde, and MEN buffer [20 mM 3-(N-morpholino)propanesul-
phonic acid, 1.0 mrvi EDTA, 5.0 m sodium acetate, pH 7.0] for 15
minutes at 68°C and electrophoresed in 1% agarose gels contain-
ing 2.2 M formaldehyde. After electrophoresis, RNA was stained
with ethidium bromide and transferred to Zetabind nylon mem-
brane (CUNO Laboratory, Meriden, Connecticut, USA) in 20 X
SSC (1 X SSC is 0.15 M NaC1 and 0.015 M sodium citrate, pH 7.0).
Dot blot analysis was performed according to Maniatis, Fritsch
and Sambrook [19]. A concentration range of 10, 5, and 2.5 jig
total RNA was applied onto nylon membrane using a dot blot
apparatus (Bio-Rad). Following transfer the filters were rinsed in
3 x SSC and baked at 80°C for two hours. Filters were prehy-
bridized for three hours in 0.5 M NaPO4 buffer (pH 7.0), contain-
ing 1 mM EDTA, 7% SDS, 1% bovine serum albumin and 50
j.tg/ml denatured salmon sperm DNA, and hybridized in the same
buffer with 32P-labeled probe at 65°C for 16 to 24 hours. Following
hybridization, the filters were washed twice with 2 X SSC, 0.1%
SDS for 30 minutes at room temperature and twice with 0.2 X
SSC, 0.1% SDS at 65°C. Filters were autoradiographed and the
mRNA levels at the dot blots were quantitated using storage
phosphor technology (Molecular Dynamics, Sunnyvale, Califor-
nia, USA).
The mouse al(IV) collagen cDNA probe (pPE131) used in the
Northern and dot blot experiments was a gift from Dr. M.
Kurkinen [20]. Human al(I) collagen cDNA (Hf677) was pur-
chased from American Type Culture Collection (ATCC). North-
ern analysis of mouse whole kidney RNA showed specific hybrid-
ization with both cDNA probes confirming previously described
results [21]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as a loading control for the blots. The probes were labeled
with 32P dCTP (3,000 CiJmmol) using a random primed labeling kit
(Boehringer Mannheim, Mannheim, Germany) as described by the
manufacturer. Specific radioactivity ranged between 0.5 to 2* io
cpml jig.
mRNA levels were expressed as means standard deviations.
Statistical significance (defined as P 0.05) was evaluated using
the unpaired t-test.
In situ hybridization
Paraffin-embedded kidney tissues were pretreated, hybridized
and washed according to Wilkinson and Green [22] with minor
modifications. One hundred m instead of 10 mM DTT was used
in the hybridization buffer. Furthermore, the sections with hybrid-
ization mix were kept at 80°C for 10 minutes prior to the 0/n
hybridization. For our probes it appeared necessary to wash at the
stringent conditions described in the protocol. The cDNA tem-
plate for the in vitro transcription of [35S]RNA probe to al(IV)
collagen was a gift of Dr. P.D. Killen, University of Michigan
Medical School (Ann Arbor, Michigan, USA) [23]. Specificity was
demonstrated by Northern blot hybridization with both the sense
and the anti-sense 32P-labeled riboprobes under the same condi-
tions as in the in situ hybridization experiments. The sections were
counterstained with HE, and studied with light, and reflection
contrast microscopy. To be able to compare the mRNA expres-
sion in kidney tissues from different experimental animals, sec-
tions from several individual mice were put on one glass slide.
Results
Proteinuria
Effect of CsA dose. By determining the amount of albumin in the
urine of the animals we monitored the progression of proteinuria
due to the development of glomerulonephritis. In the first exper-
iment the effect of the CsA dose was investigated. Five groups of
mice were injected with parental lymphocytes. Four of these
groups were treated with 250, 100, 50, or 10 mg CsA/kg body
wt!week, respectively, starting in week 2. One GvHD group was
left untreated. An additional group of six mice was administered
250 mg CsA/kg body wtlweek. The albumin excretion of the
untreated animals in Group 1A rose sharply and reached the
highest levels in week 12. Low dose CsA administration (50 or 10
mg) induced no significant differences in proteinuria as compared
to the untreated mice. Clinically these animals looked more ill
than the untreated mice; they also had to be sacrificed in week 8,
before the end of the experiment. Injection of 100 mg CsA/kg!
week significantly reduced the proteinuria in week 4 (P < 0.001).
However in week 6 the proteinuria of these mice was as high as
that in all the other GvHD groups. In contrast, GvHD mice
injected with 250 mg CsA showed a significant (P 0.0001)
decrease in proteinuria throughout the entire course of the observa-
tion period, that is, until week 12. Administration of the highest dose
of CsA without GvHD induction did not result in the development of
proteinuria (Fig. 1A).
Effect of starting point of CsA treatment. In the second experi-
ment administration of 250 mg CsA/kglweek was started four or
six weeks after the induction of chronic GvHD. The experimental
mice which were treated from week 6 on were divided into two
groups; a proteinuric group and a non-proteinuric group. Mice
which showed more than 100 jig albumin excretion/18 hr in their
urine were considered proteinuric. CsA treatment was started at
this moment. Starting the CsA injections in week 4 (Group 2B)
completely prevented the onset of proteinuria. In week 6 the
difference in albumin content of the urine between mice in Group
2 and those in Group 2D was statistically significant (respectively
2,761 3,375 and 36 22 jig/18 hr, P < 0.001). The albumin
content of the urines from non-proteinuric mice (Group 2')
remained low until the end of the experiment by CsA treatment.
However, the development of severe proteinuria in mice of Group
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Fig. 1. Course of mean urina,y protein excretion of mice suffering from
chronic GvHD and treated with CsA. The arrow indicates the starting point
of CsA treatment. (A.) Experiment 1: Several doses of CsA were injected
2 weeks after induction of GvHD. Administration of 100mg CsA/kg/week
delayed the onset of proteinuria. The highest dose (250 mg/kg/week)
prevented the development of proteinuria during the entire course of the
disease. Symbols are: (.-) GvHD untreated, (-*-) GvHD 10 mg CsA,
(-a-) GvHD 50 mg CsA, (-*-) GvHD 100 mg CsA, (+) GvHD 250 mg
CsA, (-'a-) control 250 mg CsA. (B.) Experiment 2: Administration of 250
mg/kg/week CsA starting at week 6 prevented proteinuria only if the mice
did not yet show signs of proteinuria. Symbols are: (*) GvHD untreated,
(--) non-proteinuric at week 6, (--) proteinuric at week 6.
2' could not be prevented or delayed. The onset of proteinuria in
this group was identical to that of GvHD mice without CsA
treatment (Fig. 1B).
An additional group of untreated control mice was divided six
weeks after the induction of GvHD into a subgroup (N 5)of
animals which were already proteinuric (726 1293 mg/18 hr),
and a subgroup of mice (N = 4) which did not show proteinuria
(82 20 mg albumin/18 hr, P  0.0001). Twelve weeks after the
induction of GvHD both subgroups were proteinuric (18184
10706 mg/18 hr and 19565 14071 mg/18 hr, respectively), and
there was no statistically significant difference between the groups
(P = 0.299).
Autoantibodies
The presence in the circulation of autoantibodies directed
against ss and dsDNA, GBM, and RTE was measured by ELISA.
Fig. 2. Production of anti-glomerular basement membrane (GBM) antibod-
ies by EL ISA in the sera of mice at different time points after the induction of
GvHD. The arrow indicates the starting point of CsA treatment. (A.)
Experiment 1, (u) GvHD untreated, (--) GvHD 10 mg CsA, (-6-)
GvHD 50 mg CsA, (-*-) GvHD 100 mg CsA, (-1--) GvHD 250 mg CsA,
(-'a-) control 250 mg CsA. (B.) Experiment 2, (u) GvHD untreated, (-a-)
non-proteinuric at week 6, (*) proteinuric at week 6.
Figure 2 shows the autoantibody titers against GBM during the
course of the disease. The autoantibody titers against ssDNA,
dsDNA, and RTE showed comparable patterns (data not shown).
Treatment of GvHD mice with 10, 50, or 100 mg CsAJkg/week
from week 2 on did not influence the titers of any of these
autoantibodies, that is, the levels in the sera were comparable to
those in untreated GvHD mice. Administration of 250 mg CsA/
kg/week from week 2 on delayed the development of all autoan-
tibodies tested for (Fig. 2A). However, when treatment with this
amount of CsA was started in week 6 similar levels of autoanti-
bodies were measured in the sera of treated and untreated mice
(Fig. 2B). Moreover, no differences were observed between the
proteinuric and non-proteinuric mice in experiment 2 also when
CsA treatment had prevented the onset of proteinuria (Fig. 2B).
Kidneys were examined for the presence of immune deposits by
direct immunofluorescence. Results are summarized in Table 1.
Induction of GvHD resulted in granular depositions of IgG in the
mesangium as well as along the glomerular capillary walls. IgG
was present from week 4 until the end of the experiment (week
12). Mesangial deposits of 1gM were found to low amounts in
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Table 1. Dose-dependent inhibition of Ig and complement deposition
by CsA during development of GvHD as determined semiquantitatively
by direct immunofluorescence
IgG 1gM C3
Week GBM MES GBM MES GBM MES
Untreated GvHD 4 + + + +
12 ++ +++ + -1-++ + +
GvHD,1OCsA 4
12
++
++
++
+++
±
±
+
++
±
+
++
+
GvHD, 50 CsA 4 + + + + ± + + + +
12 ++ +++ + ++ + ++
GvHD, 100 CsA 4 + + — ± ± ±
12 ++ ++ + ++ + +
GvHD, 250 CsA 4 ± ± — ± — —12 + + — + + ++
Control, 250 CsA 4 — — — — — —
12 — — — — — —
Abbreviations are: GBM, glomerular basement membrane; mes, me-
sangium. Scoring refers to staining intensity. Staining was either absent
(—), or varied from minute (±) to abundant (+++).
weeks 4 and 6, but were dramatically increased towards the end of
the disease. The complement component C3 was observed in the
mesangium and faintly in the glomerular capillary loops four
weeks after induction of GvHD. In the final stage of the disease
the amount of C3 in the mesangium was reduced as compared to
the earlier stages.
Treatment with the two lowest doses of CsA in experiment
1 resulted in IgG, 1gM, and C3 deposition patterns comparable to
those seen in untreated GvHD mice. Injection of 100 mg CsA
(Group 1D) resulted in a small decrease in C3 staining intensity in
week 4 of the disease. Later the staining intensity was similar to
that in untreated GvHD mice. The staining intensity for IgG and
1gM in Group i' in week 4 was similar to or slightly less than that
in untreated GvHD mice, but similar in the end stage. Admin-
istration of the highest CsA dose (Group 1E) resulted in a
remarkable reduction to an almost absence of IgG, 1gM, and C3
deposition. In week 12 some deposition of antibodies and C3 was
observed, but this was still less than that in the kidneys of
untreated GvHD mice. When the administration with 250mg CsA
was started six weeks after the first injection with donor lympho-
cytes (Groups 2 and 2D) direct immunofluorescence in week 12
showed deposition of 1gM and C3 comparable to that in the
kidneys of untreated GvHD mice. CsA treatment resulted in a
slight decrease in staining intensity for IgG in the mesangium, but
not in the GBM. There were no differences in IgG, 1gM, or C3
distribution or intensities between groups of mice in experiment 2.
Administration of 100 or 250 mg CsA into normal control mice
(Groups 1" and 1G) did not result in deposition of either IgG,
1gM, or C3.
Motphology
Light microscopy of kidney sections of untreated GvHD mice
showed a lupus type of glomerular disease with glomerular
proliferation as well as membranous nephritis, complicated by
glomerulosclerosis starting 10 weeks after the induction of GvHD,
confirming earlier results [7]. In week 12 glomerulosclerosis was
observed in 48 to 90% of the glomeruli, varying between individ-
ual mice. At this stage, Bowman's capsule was markedly thick-
ened, especially at the hilus. Furthermore, adhesions were seen
C
Fig. 3. (A.) Glomendus in week 12 in untreated chronic GvHD showing
expansion of the mesangial matrix, thickening of the GBM, adhesions to
Bowman's capsule, and segmental sclerosis (arrow). (B.) Kidney section of
a week 6 GvHD mouse in Group 10 which was treated with 100 mg
CsA/kg/week starting at week 2 showing expansion of the mesangial matrix
and thickening of the glomerular capillary walls. (C.) Kidney section of a
GvHD mouse in Group 2 which was treated with 250 mg CsAJkg/week
starting at week 6, showing no abnormalities. (PAS staining, original
magnification 300x).
between the glomerular tuft and Bowman's capsule (Fig. 3A).
Kidneys from mice treated with 10, 50, or 100 mg CsA/kg/week in
experiment 1 (Groups 10) showed the same morphological
A
B
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features as described for untreated GvHD mice (Fig. 3B). In week
12 the percentages of sclerotic glomenili in these groups varied
between 34 and 76%. When the development of proteinuria was
prevented by CsA treatment (Groups 1E 2B and 2C) neither
proliferation, matrix expansion, nor glomeruloscierosis was ob-
served by light microscopy throughout the observation period
(Fig. 3C). CsA administration by itself did not result in morpho-
logical abnormalities in the kidneys.
All untreated GvHD mice and those GvHD mice in which the
CsA treatment had not reduced proteinuria (Groups and
2.D) showed massive T cell infiltrates in their kidneys in the final
stage of the disease (week 12) as determined by immunofluores-
cence using antibodies against CD3. The inflammatory cells were
predominantly located around the vessels and in the interstitium.
Only very few to no T cells were present in the glomeruli. In those
cases where glomerulonephritis had been prevented by CsA
administration, T cell infiltrates were not observed.
mRJ"JA analysis
The effect of CsA treatment on the transcription levels of the
ECM components al(I) and al(IV) collagen in whole kidney
cortex was investigated. Results of dot blot analysis are shown in
Figure 4. In week 12 untreated GvHD mice showed a 3.8-fold
(experiment 1) and 6.8-fold (experiment 2) increase in al(I)
collagen steady-state mRNA levels as compared to healthy con-
trol mice. The csl(IV) collagen steady-state mRNA levels of
untreated GvHD mice in week 12 of the observation period were
increased 7.6-fold in experiment 1 and 4.8-fold in experiment 2. In
experiment 1 administration of 250 or 100 mg CsAIkg/week
resulted in a decrease in mRNA steady-state levels for both
collagen types. Administration of 50 mg CsA/kglweek had a
comparable effect on the ai(I) collagen mRNA level. However,
these levels were still higher than those of normal mice. No
difference in cwl(IV) collagen mRNA levels was observed between
untreated GvHD mice and mice, which had received 50 mg
CsAlkglweek. Injection of 10 mg CsA/kg!week into GvHD mice
increased the mRNA levels for both ECM components, although
this was not significant for cvl(IV) collagen. CsA administration
(250 mg/kg/week) before the onset of proteinuria in GvHD mice
(Group 2C) reduced the mRNA levels for both collagen types,
whereas this was not achieved when the experimental mice
already showed signs of proteinuria at the start of treatment.
Control injections with the highest dose of CsA for six weeks
(Group 1G) resulted in only slightly increased steady-state colla-
gen mRNA levels as compared to those in normal healthy control
mice.
In situ hybridization with an anti-sense riboprobe coding for
ni (IV) mRNA showed minor amounts of silver grains in glomer-
uli and tubular epithelial cells in kidney sections of normal mice.
The silver grain density was hardly above background level.
Widespread distribution of silver grains in the perivascular,
interstitial, and periglomerular regions was observed in kidneys of
untreated week 12 GvHD mice (Fig. 5B), and of proteinuric,
diseased mice of Group 2D (Fig. 5C). However, kidney sections
from mice which had been treated with CsA starting before the
onset of proteinuria showed no increase in silver grain density
(Fig. 5D) as compared to those of normal mice. Administration of
250 mg CsAJkg/week for six weeks in normal control mice resulted
in a very minor increase in the amounts of silver grains (Fig. SE).
Hybridization with the sense-riboprobe showed only a slight
0
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Fig. 4. Whole kidney tissue mRNA levels for al(I) and al(IV) collagen in
normal mice, in treated or untreated GvHD week 12 mice, and in CsA control
mice as determined by dot blot analysis. The results are relative to the
expression in normal control animals, of which the values were normalized
to 1,0. mRNA levels were corrected for the spotted amounts by compar-
ison with the hybridization signal for GAPDH mRNA. (A.) Experiment 1,
(B.) Experiment 2. Hatched bars = al(IV) collagen, open bars = al(I)
collagen. Values are means so. Statistical significance was determined
for CsA treated GVHD mice as compared to untreated GVHD mice, *
P 0.05.
random distribution of silver grains indicating no specific hybrid-
ization (Figs. 5 F and G).
Discussion
In the present study we investigated the effect of the powerful
immunosuppressive drug CsA on the development of glomerulo-
sclerosis as a complication of immunologically mediated glomer-
ulonephritis. Improvement of the diagnosis and treatment of
patients requires a better understanding of the mechanisms
underlying the preventive action of drugs on the development of
glomerulonephritis and glomeruloscierosis. There are several
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Fig. 5. Micrographs from sections hybridized for al collagen type Win GvHD week 12 mice from experiment 2. Normal mice (A) show minor amounts of
silver grains in glomeruli and in tubular epithelial cells. The silver grain density in sections of normal mouse kidney is hardly above the background level.
Untreated GvHD mice (B), and mice which are treated from week 6 on with 250 mg/kg CsA after the onset of proteinuria (C) show increased silver
grains in the perivascular, interstitial, and periglomerular regions, as compared to kidney sections of normal mice (A) and those of GvHD mice which
did not have signs of proteinuria in week 6 and were treated in the same way (D). Administration of 250 mg CsAJkg/week for 6 weeks in normal control
mice resulted in very minor wide-spread increased amounts of silver grains (E). Hybridization with a sense al (IV) collagen riboprobe as control resulted
in minor diffuse distribution of silver grains in both non-proteinuric mice of Group 2 (F), and proteinuric, diseased mice of Group 2' (C). Original
magnification 10 X 25.Arrows point to increased amounts of silver grains in the periglomerular regions, arrowheads to those in the interstitial regions.
Publication of this figure in color was made possible by a grant from Sandoz B.V., Uden, The Netherlands.
other experimental models of immunologically mediated nephritis mechanisms involved in proteinuria, as a rapid reversal of pro-
in which treatment with CsA has been investigated [reviewed by teinuria was obtained in several instances despite the persistence
Borel 24]. The drug interferes mainly with the cellular effector of autoantibodies and circulating immune complexes. However,
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there are also studies reporting suppressed autoantibody forma-
tion. These discrepancies can in most cases be ascribed to
differences in the amounts of CsA given, the moment of therapy
initiation, the route of administration, or a combination of these
factors. Because of this wide variation between studies, we
performed several experiments in order to get a clear view of
the effects of CsA administration dose and starting point in
murine chronic GvHD. Furthermore, we investigated the effect of
CsA on the ECM mRNA levels in this model.
A pilot study had shown that i.p. injection of 100 mg CsA/kg/
week delayed the onset of proteinuria only if treatment was
started two weeks after the first injection of donor lymphocytes.
No effect was measured when administration of CsA was started
later in the disease.
To investigate which dose of CsA gave the optimal effect, that
is, the strongest suppression of the disease without detectable
nephrotoxic side effects, we compared four doses which were all
started in week 2. Since the development of proteinuria in the
pilot study had been delayed but not totally suppressed, a dose
higher than the one used in the pilot experiment was also
included. Indeed, administration of 250 mg CsAJkg/week pre-
vented abnormal leakage of proteins into the urine during the
entire course of the disease. The use of 10 or 50 mg CsA/kg!week
did not influence the time of onset of proteinuria. Even more,
some of the mice treated with these low doses had to be sacrificed
before the end of the experiment, because they were clinically so
ill that they would not have survived much longer. Increased
mortality by CsA has also been found in MRLIIpr mice, another
experimental model for lupus nephritis [25]. In the ELISA and
direct immunofluorescence studies it appeared that the autoanti-
body levels in the sera of GvHD mice treated with 250 mg CsA
from week 2 on were decreased. In our model of chronic GvHD
in mice a T cell induced abnormal B cell proliferation leads to the
production of autoantibodies directed against an array of antigens
including dsDNA, histones, and laminin. Inhibition of T cells
reduces the autoantibody production by B cells and consequently
the development of glomerulonephritis. This may implicate that
the early administration of this high dose of CsA had interfered
with the onset of chronic GvHD itself. Therefore, in the second
experiment high dose CsA treatment was started four or six weeks
after the first injection of parental lymphocytes. The animals
which were treated from week 6 on, were divided into two groups.
Mice in Group 2D had more than 100 g albumin/24 hr in their
urine, whereas the urine albumin content of mice in Group 2 was
still normal in week 6. In this last group development of glomer-
ulonephritis (that is, cellular influx and proteinuria) and glomer-
ulosclerosis was prevented by the CsA treatment, without reduc-
tion of the serum autoantibody levels and deposition of
immunoglobulins and complement components in the glomeru-
lus. The animals in Group 2D continued to develop glomerulone-
phritis and glomerulosclerosis. From these and previous experi-
ments it was known that animals which were still non-proteinuric
in week 6 always developed proteinuria when no treatment was
applied. A similar phenomenon has recently been found by Ren,
van Liew and Noble in rats with proliferative immunecomplex
glomerulonephritis in chronic serum sickness [26]. When CsA
therapy was started before the onset of proteinuria, progression
from moderate to severe nephritis did not occur. These authors
speculated that in their model a very brief T cell residence in
glomeruli in the early stage of disease is sufficient to trigger the
pathogenic events that lead from moderate to severe nephritis.
Therefore, it is critical to administer CsA before the influx of T
cells into the glomerulus occurs. In previous studies we also
observed inflammatory cells which had infiltrated the glomerulus
two to six weeks after induction of GvHD. The identity of these
cells is currently under investigation. The influx of CD3-positive
cells in the interstitial and perivascular regions in the final stage of
GvHD should not be confused with the early glomerular infiltra-
tion of inflammatory cells. The T cell influx we describe in this
study is probably part of a late secondary interstitial inflammatory
reaction. This late influx did not occur in non-proteinuric mice
(Group 2C), but was very profound in untreated GvHD mice
(Group 2A) and in proteinuric GvHD mice (Group 2D).
The mechanism by which CsA prevents the increase of ECM
mRNA levels and subsequent matrix expansion, and finally devel-
opment of glomerulosclerosis and a secondary interstitial inflam-
matory reaction, in our model is still unclear. The search for the
mechanism of immunosuppression by CsA is still not completed,
as reviewed by several investigators [27—29]. Currently, CsA is
thought to inhibit both T and B lymphocyte proliferation by
antagonizing the Ca2 signal that plays a role in initiating this
process (summarized by Kay [9]). It is the response of the cell to
the Ca2 signal that is prevented, rather than the generation of
the signal itself. The Ca2 signal is essential for the induction of
the synthesis of mRNA coding for several lymphokines [30—32]. It
is now clear that this drug also acts on cell types other than T
lymphocytes, such as mast cells, basophils, and neutrophils [33,
34]. CsA has also been reported to inhibit the production of
lymphokines such as IL-i synthesized by cells of the monocyte!
macrophage lineage [30, 35, 36], and to affect their antigen-
presenting function [37]. In our model, administration of CsA may
therefore suppress the increased ECM production in the diseased
kidneys via its effect on lymphokine production by immunologic
cells. However, CsA has also been shown to affect non-immuno-
logic cells. Both endothelium-dependent vasodilation and vascu-
lar smooth muscle contraction in rat aorta are, depending upon
the stimulus applied, affected by chronic CsA treatment [38].
Proliferation of renal mesangial cells was inhibited in an indirect
way, that is, via an effect on endothelial mediators, which normally
inhibit the mitogenic effect of endothelin [391. The drug also
activates endothelial cells [40, 41], although no effect on cytokine
production of endothelial cells was observed. In epithelial cells the
secretion of IL-6 after stimulation with bacteria and TNFa was
inhibited by CsA [42]. This is of interest since IL-6 is thought to
play a role in several kidney diseases [43, 44]. Furthermore,
development of glomeruloscierosis might also be influenced by
the direct inhibitory effect of low CsA concentrations on throm-
boxane synthase [45], since thromboxane has been shown to
increase the steady-state mRNA levels for several ECM proteins
[46], and chronically diseased kidneys produce increased quanti-
ties of this metabolite [47]. Finally, the drug has an acute effect on
renal vascular resistance [42]. In earlier reports [7, 21] we
described that ECM expansion and thickening of the GBM in
week 6 of GvHD were accompanied by increases in the amounts
of laminin, fibronectin, and the collagen types IV and VI. The
mRNA steady-state levels encoding for these components were
already increased before morphological changes were detectable.
The end-stage glomerular sclerotic lesions, developing 10 weeks
after disease induction, were mainly the result of specific accumu-
lation of exogenous fibronectin [48]. In earlier reports we and
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others speculated about the pathogenesis of glomerulonephritis
and glomeruloscierosis [49, 50]. We hypothesized that the early
formation of immune complexes in kidney glomeruli leads to an
inflammatory reaction in these glomeruli. Resident glomerular
cells are activated and start to produce ECM components and
several cytokines. These mediators may trigger a secondary
interstitial inflammatory reaction, resulting in the overexpression
of ECM mRNA by recruited cells. In our model, treatment with
CsA can still prevent the occurrence of these events despite the
presence of autoantibodies. Therefore, the direct action of CsA
on the residential glomerular cells may contribute to the suppres-
sion of the events which are otherwise leading to the development
of glomerulosclerosis. This hypothesis is supported by our in situ
hybridization findings, showing decreased message for al(IV)
collagen in both glomeruli and interstitium after treatment with
CsA.
The fact that in GvHD mice the steady-state mRNA levels for
ECM components both in whole kidneys and in isolated glomeruli
were already increased in week 4 [21], that is, before morpholog-
ical changes were detectable, may possibly indicate an important
diagnostic role for mRNA steady-state levels. This diagnostic
value is supported by the present study, in which it is shown that
the development of glomerulonephritis and glomerulosclerosis
can still be prevented even if CsA treatment is started in week 6.
Thus, although the value of proteinuria as a good and easily
quantifiable prognostic indicator is not disputed, changes in
mRNA levels may be detected before the onset of proteinuria and
thus allow for earlier treatment and more effective prevention of
further disease. The importance of early mRNA analysis has also
been stressed for human diseases by Striker [51]. This author
suggests the application of mRNA analysis of renal biopsies as a
tool of special interest in slowly progressive diseases which may
potentially provide information not currently available for the
individual patient, because clinical and morphological markers
appear relatively late and may not accurately reflect the rate of
progression.
In our study substantial reduction in mRNA levels for al(I) and
al(IV) collagen was also observed after treatment with subeffi-
cacious (50 and 100 mg/kg/week) doses of CsA (experiment 1).
Although these reductions in mRNA levels were only statistically
significantly different from those in untreated GvHD mice in the
group of mice which were treated with 250 mg CsA/week, this
raises the possibility that the benefits of CsA to prevent renal
disease can be dissociated from the effects on collagen mRNA
levels. Indeed, low ECM mRNA levels do not guarantee that mice
will not develop renal disease. Extensive post-transcriptional
regulation of matrix protein synthesis should be taken into
account as well. However, in our studies we do find a positive
correlation of high levels of matrix mRNA with development of
renal disease.
It is known that treatment with CsA sometimes leads to side
effects, such as renal nephrotoxicity. A precise determination of
kidney sections from normal control mice injected with 250 mg
CsA was performed to exclude a nephrotoxic effect of this high
dose of the drug. Several reports have been published in which
nephrotoxicity has been described with even lower doses of CsA
than those used in our experiments [41, 52]. However, no neph-
rotoxic effects of CsA were observed in our experimental mice.
Elevated renal mRNA levels for ECM components after CsA
administration have been described by Nast et al [53], and Wolf
and Neilson [54]. In the studies reported here the mRNA levels
for al(I) and al(IV) collagen in the kidneys at the very end of the
experiment were also slightly increased when high doses of CsA
(100 and 250 mg/kg/week) were administered, however no en-
hancement of collagen I protein expression was observed as
determined by immunofluorescence (data not shown). The re-
ports mentioned above describe experiments performed in rats
and humans. In mice the nephrotoxicity limit is probably different
from other species. Furthermore, differences in chronic toxicity
may be related to intermittent administration of the drug as
opposed to daily treatment.
Wood et al noted a worsening of the glomerular injury when
CsA was administered in addition to anti-GBM antibodies [55].
It might be speculated that a similar event occurs in our model,
but only when GvHD mice are treated with the lowest dose of
CsA used in our studies (10 mg/kg/week). Administration of
this dose of CsA had no effect on the al(IV) collagen-mRNA
levels, but resulted in increased mRNA levels for al(I) colla-
gen as compared to those in untreated GvHD mice. The
percentage of sclerotic glomeruli in the kidneys of mice treated
with this low dose of CsA was not increased as compared to
that in untreated GvHD mice. The mechanism underlying this
mRNA increase in GvHD after administration with low doses
of CsA is unknown.
In summary, treatment with 250 mg C5A/kg/week can prevent
the development of glomerulonephritis and glomerulosclerosis in
this model of lupus nephritis. However, therapy has to be started
early in the disease, that is, before the onset of proteinuria. This
indicates the need for early diagnostic parameters. Serum auto-
antibody, and glomerular matrix mRNA steady-state levels may
possibly be valuable in this context.
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